Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Emergent Biosolutions Inc (NYSE: EBS) was $8.34 for the day, down -14.20% from the previous closing price of $9.72. In other words, the price has decreased by -$14.20 from its previous closing price. On the day, 1.91 million shares were traded.
Ratios:
Our analysis of EBS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.27. For the most recent quarter (mrq), Quick Ratio is recorded 1.47 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 12 ’24 when DeGolyer Donald W sold 25,000 shares for $10.91 per share. The transaction valued at 272,750 led to the insider holds 111,100 shares of the business.
White Marvin L sold 14,287 shares of EBS for $171,015 on Nov 11 ’24. The Director now owns 54,092 shares after completing the transaction at $11.97 per share. On Nov 12 ’24, another insider, DeGolyer Donald W, who serves as the Director of the company, bought 25,000 shares for $11.77 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.40 while its Price-to-Book (P/B) ratio in mrq is 0.89.
Stock Price History:
Over the past 52 weeks, EBS has reached a high of $15.10, while it has fallen to a 52-week low of $1.48. The 50-Day Moving Average of the stock is -13.63%, while the 200-Day Moving Average is calculated to be -2.57%.
Shares Statistics:
A total of 54.10M shares are outstanding, with a floating share count of 52.82M. Insiders hold about 2.52% of the company’s shares, while institutions hold 64.09% stake in the company.
Earnings Estimates
The current assessment of Emergent Biosolutions Inc (EBS) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $1.14, with high estimates of $1.14 and low estimates of $1.14.
Analysts are recommending an EPS of between -$0.63 and -$1.0 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is $2.07, with 1.0 analysts recommending between $2.07 and $2.07.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $268M to a low estimate of $237M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $276.6MFor the next quarter, 3 analysts are estimating revenue of $279M. There is a high estimate of $279M for the next quarter, whereas the lowest estimate is $279M.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.12B, while the lowest revenue estimate was $1.09B, resulting in an average revenue estimate of $1.1B. In the same quarter a year ago, actual revenue was $1.05BBased on 2 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.17B and the low estimate is $1.09B.
